

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064738 A3

(51) International Patent Classification⁷: **C07D 211/06**,
A61K 31/4468, A61P 25/14, 25/16, 25/18, 25/28, 25/24,
25/06

(21) International Application Number:
PCT/US2004/001234

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/441,406 16 January 2003 (16.01.2003) US
60/479,346 17 June 2003 (17.06.2003) US

(71) Applicant (for all designated States except US): **ACADIA PHARMACEUTICALS INC.** [US/US]; 3911 Sorrento Valley Blvd., San Diego, CA 92121-1402 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEINER, David, M.** [US/US]; 4915 Muir Avenue, San Diego, CA 92107 (US). **DAVIS, Robert, E.** [US/US]; 13272 Glencliff Way,

San Diego, CA 92130 (US). **BRANN, Mark, R.** [US/US]; 2950 Racetrack View Drive, Del Mar, CA 92014 (US).


(74) Agent: **HART, Daniel**; Knobbe, Martens Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES



(57) Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT_{2A/2C} receptor inverse agonist, demonstrate *in vivo* efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT_{2A/2C} receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

WO 2004/064738 A3



Published:

— with international search report

(88) Date of publication of the international search report:

25 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/001234

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/06 A61K31/4468 A61P25/14 A61P25/16 A61P25/18
A61P25/28 A61P25/24 A61P25/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 877 173 A (FARBER NURI B ET AL) 2 March 1999 (1999-03-02) claims 1,30	9-13
X	US 3 983 234 A (SAYERS ANTHONY CAMPBELL) 28 September 1976 (1976-09-28) column 1, line 1 - line 17	9-13, 17-20
X	FRIEDMAN J H: "Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 9, no. 3, 1 May 1994 (1994-05-01), pages 321-324, XP009032726 page 321, right-hand column, paragraph 3 page 323, right-hand column, paragraph 3 ----- -/--	25-28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 July 2004

Date of mailing of the international search report

08/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, T

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/001234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YOSHIDA K ET AL: "Marked improvement of tardive dystonia after repoacing haloperidol with risperidone in a schizophrenic patient" CLINICAL NEUROPHARMACOLOGY, vol. 21, no. 1, 1998, pages 68-69, XP009032725 page 69, left-hand column - right-hand column	25-28
X	DELECLUSE F ET AL: "A case of tardive tremor successfully treated with clozapine" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 13, no. 5, September 1998 (1998-09), pages 846-847, XP009032724 the whole document	25-28
X	FACTOR S A ET AL: "Clozapine prevents recurrence of psychosis in Parkinson's disease" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 7, no. 2, 1992, pages 125-131, XP009032679 page 130, right-hand column, paragraph 2	32-35, 39
X	FACTOR ET AL: "Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 16, no. 1, January 2001 (2001-01), pages 135-139, XP009032680 page 138, right-hand column, paragraph 2	32-35, 39
X	US 2002/165225 A1 (KANKAN RAJENDRA N ET AL) 7 November 2002 (2002-11-07) page 1, right-hand column, paragraph 8 - page 2, left-hand column, paragraph 1 claims 12,16	32-35, 39-44, 46
X	US 6 358 698 B1 (BRANN MARK R ET AL) 19 March 2002 (2002-03-19) claims 9,10 column 1, paragraph 1 column 4, line 60 - line 64 column 5, line 59 - column 6, line 14 tables 2,3	32-35, 39-44, 46
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/001234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HERRICK-DAVIS ET AL: "Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine_{2C} Receptors" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 295, no. 1, October 2000 (2000-10), pages 226-295, XP001182089 figures 1-3 table 1</p> <p>-----</p>	1-86

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US2004/001234

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5877173	A	02-03-1999	NONE	
US 3983234	A	28-09-1976	NONE	
US 2002165225	A1	07-11-2002	US 6348458 B1 AT 6739 U1 AU 2017601 A CA 2395774 A1 DE 20023184 U1 DK 200300161 U1 DK 200300221 U1 DK 200300222 U1 EP 1246827 A1 WO 0147933 A1 NZ 519926 A ZA 200205228 A IN 187439 A1	19-02-2002 25-03-2004 09-07-2001 05-07-2001 03-04-2003 16-06-2003 25-08-2003 25-08-2003 09-10-2002 05-07-2001 27-02-2004 30-06-2003 27-04-2002
US 6358698	B1	19-03-2002	AU 6391299 A WO 0020636 A1	26-04-2000 13-04-2000